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Abstract: 
The endo-lysosome system is involved in endocytosis, protein sorting and degradation as well as 
autophagy. Numerous toxins and pathogens exploit this system to enter host cells and exert their 
deleterious effects. Modulation of host endo-lysosome pathway may restrict multiple toxins 
intoxication as well as pathogen infection. ABMA, selected from a high-throughput screening against 
the cytotoxicity of ricin toxin, exhibits a broad-spectrum anti-toxin and anti-pathogen activity. Here, 
we show that ABMA selectively retains endocytosed protein and toxin to late endosomes, and thus 
delaying their intracellular trafficking. It also impairs the autophagic flux by excessive fusion of late 
endosomes and autophagosomes. Its exclusive action on late endosomes and corresponding 
consequences on the endo-lysosomal pathway and autophagic flux are distinct from known inhibitors 
such as bafilomycin A1, EGA or chloroquine. Hence, besides being a broad-spectrum inhibitor of 
endocytosed toxins and pathogens, ABMA may serve as a molecular tool to dissect endo-lysosome 
system-related cellular physiology and mechanisms of pathogenesis.
1. Introduction
Outbreaks of emerging pathogens without licensed treatments and with microbial drug-resistance are 
major public health threats [1-3]. An emerging strategy in anti-infectious drug discovery is to look for 
therapies targeting host functions, which are exploited by pathogens for infection and/or growth in 
host cells [4-13]. The endo-lysosomal system is made of dynamic organelles (early endosomes, 
recycling endosomes, late endosomes and lysosomes) into which cargo molecules are internalized, 
transported, recycled or digested for cellular homeostasis. It is a predominant pathway used by toxins 
and pathogens to enter host cells before escaping to the cytoplasm or, for some parasites and bacteria, 
building a vacuole in which they proliferate [14]. Moreover, autophagy converges into the late 
endosome/lysosome system through the fusion of autophagosome with endosomes and lysosomes to 
accomplish autophagic degradation of unnecessary or dysfunctional cellular components, which is an 
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Several chemical molecules have been identified and used as regulators of the endo-lysosome system. 
Dynasore as well as pitstop-1 and -2 blocks dynamin- and clathrin-dependent endocytosis [16]; EGA 
inhibits trafficking of toxins and pathogens in early endosomes with an unknown cellular target [11]; 
bafilomycin raises endosomal pH by specifically inhibiting vacuolar-type H+-ATPase [17]; 
chloroquine [18] and several other inhibitors (e.g. amodiaquine [8]) block lysosomal degradation by 
inactivating lysosomal hydrolases; Tetrandrine inhibits lysosomal functions by specifically blocking 
the endo-lysosomal channel two-pore channel 2 (TPC2) [19]. These molecules, without exception, 
exhibit broad-spectrum anti-pathogen activities [8, 11, 18, 20]. Furthermore, these specific molecular 
tools contribute substantially to the understanding of intracellular trafficking and infection 
mechanisms of known as well as emerging pathogens [11, 18, 21].
Previously, we performed a cell-based high-throughput screening (HTS) for inhibitors of ricin toxin 
and found three inhibitors [22]. Retro-1 and -2, selectively block retrograde trafficking of toxins and 
pathogens at the early endosome-TGN (trans-Golgi Network) interface [22]. Safety and efficacy 
against ricin of another hit, ABMA, has been validated in vivo [12]. Moreover, ABMA was found to 
protect cells against four bacterial toxins (diphtheria toxin from Corynebacterium diphtheriae (DT), 
lethal toxin from Bacillus anthracis (LT), toxin B from Clostridium difficile (TcdB), lethal toxin from 
Clostridium sordellii (TcsL)), as well as four viruses (Ebola, Rabies, Dengue-4 and Herpes simplex 
virus type 2 (HSV-2)), two species of Chlamydiales intracellular bacteria (Simkania negevensis (Sn), 
Chlamydia trachomatis (Ctr)) and the parasite Leishmania infantum at μM level [12, 23].
Here, we further demonstrate that ABMA delays endo-lysosomal trafficking at the level of late 
endosomes, thereby retaining endocytosed pathogens and proteins in this compartment. Furthermore, 
ABMA stimulates the fusion of late endosomes with autophagosomes, forming amphisomes in 
excess, and thus disrupting the autophagic flux. Its mechanism of action is different from known 
endo-lysosomal trafficking inhibitors, which suggests that ABMA is a selective tool for the study of 
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2.1. ABMA and EGA, two broad-spectrum inhibitors, have apparent synergistic effect to inhibit 
the cytotoxicity of diphtheria toxin (DT)
As described before, ABMA, a broad-spectrum inhibitor of multiple toxins and intracellular 
pathogens [12, 23], was selected from a cell-based HTS for inhibitors of ricin toxin [22]. ABMA 
induces late endosomes accumulation [12], however, how ABMA inhibits intracellular trafficking of 
pathogens is not yet resolved. 
Another recently identified wide-spectrum anti-pathogen inhibitor, EGA, inhibits endo-lysosomal 
trafficking by direct action on early endosome [11]. Both compounds act on the endo-lysosomal 
system, but they have different anti-toxin and antiviral spectra (Table 1). For example, cytotoxic 
activity of toxin B from Clostridium difficile is acidic endosome-dependent and relies on endosomes 
to translocate into the cytoplasm [24, 25]. However, ABMA, not EGA, can inhibit its cytotoxicity. 
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In order to further analyze the mechanism of action of ABMA, we questioned whether ABMA and 
EGA could have additional or synergistic inhibitory effects on toxins that are sensitive to both 
compounds. DT is a well-identified single-pathway toxin, which relies on the acidification of 
endosomes at the early-late endosome interface to translocate its enzymatic domain into the 
cytoplasm [28, 29]. We compared the effect of each compound and their combination on the 
cytotoxicity of DT, at concentrations lower than their respective IC50s. Protection factor (R, R= IC50 
drug/ IC50 DMSO, ratio of toxin concentrations to inhibit half of maximal protein biosynthesis of cells in the 
presence of drug or DMSO) is used to quantify efficacy of the compound at indicated concentrations 
(see our previous description [12]). ABMA at 30 µM (IC50: 62.5 M [12]) and EGA at 1.25 µM (IC50: 
9.7 M, Fig 1A) both inhibited DT with a protection factor (R) of ~5. The combination of the two 
compounds at these concentrations led to protection factors of 59.7  8.5 against DT (n=3, Fig 1B and 
1C) without additive toxicity (date not shown). Moreover, EGA at 2.5 M (R: 32.9  8.3) combined 
with ABMA at 30 µM (R: 3.9  0.06) substantially improved protection factor (R: 1645  262.8, n=3, 
Fig 1C). These values are way above the multiple of the individual protection factors, suggesting an 
apparent synergistic effect of the combination. This indicates that ABMA and EGA may inhibit DT 
cytotoxicity with different mechanism of action. Similarly, we observed that ABMA combined with 
dynasore (inhibitor of endocytosis) or tetrandrine (Tet, see description below) inhibited DT with 
largely improved R values (Fig 1D and 1E).
The epidermal growth factor (EGF), once bound to its cell-surface receptor (EGFR), is known to be 
internalized and to traffic along the endo-lysosomal pathway down to the lysosomes where it is 
degraded [30]. Thus, fluorescently labeled EGF is used as a kinetic marker of endocytosis and 
trafficking through the endo-lysosomal pathway until it is degraded in the lysosomes. To further 
dissect the kinetics of drugs’ action, we investigated the trafficking of fluorescently labeled Alexa555-
EGF in the presence of ABMA or EGA. A549 cells were incubated with Alexa555-EGF for 30 min to 
allow EGF to enter the cells by receptor-mediated endocytosis. Then, cells were incubated with the 
compounds for 4 h to examine the cellular trafficking of EGF (Fig 2A). ABMA substantially inhibited 
degradation of EGF as shown by the persistence of a strong fluorescent signal in intracellular 
compartments, compared to the DMSO control. In contrast, EGA barely prevented the degradation of 
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DMSO control. Tet, an inhibitor of lysosomal calcium channels [20], was used as a positive control of 
the blocking of lysosomal degradation and gave the strongest fluorescent signal of intracellular 
compartments after 4 h (Fig 2A). These results suggest that ABMA blocks or delays the access of 
internalized proteins to lysosomal degradation, while EGA acts at an early stage of EGF entry. To be 
note, combination of ABMA with Tet produced markedly increased efficacy in inhibiting DT 
cytotoxicity (Fig 1E), indicating they may act on endolysosomal pathway distinctively.
2.2. ABMA induces retention of EGF and DT in acidic endosomes, delays degradation of DQ-
BSA
Knowing that ABMA restricted degradation of EGF, we then used lysotracker to label acidic 
organelles of live cells and found that EGF substantially co-localized with lysotracker-labeled vesicles 
in ABMA-treated cells (Fig 2B). This indicates that ABMA inhibits EGF degradation and leads to its 
accumulation in acidic organelles. As shown before, in contrast to the DMSO control, lysotracker 
staining was more condensed and brighter in presence of ABMA indicating an enlarged volume of 
endosomes (Fig 2B), which were previously characterized as Rab7-positive late endosomes [12].
Subsequently, His-eGFP-CRM197 (eGFP-CRM197, Fig 3A) was employed to monitor how ABMA 
interfere with the intracellular trafficking of the DT. CRM197 is a nontoxic DT that has a glycine to 
glutamic acid mutation at amino acid 52 in catalytic domain, resulting in the loss of enzymatic 
activity but without change to its intracellular trafficking [31]. The N-terminal tagging with eGFP of 
the toxin allows tracking of the catalytic domain along its intracellular route, which eventually 
translocates across endosomal membrane. As early as 45 min after incubation with A549 cells, 
vesicle-shaped fluorescence from eGFP-CRM197 was visualized inside cells (Fig 3B), indicating that 
toxins were internalized and routing to the endo-lysosomal pathway. After 5 h incubation, in the 
DMSO-treated control cells, the eGFP-CRM197 signal was very weak with only a few labeled 
intracellular vesicles. In addition, no obvious co-localization with lysotracker was observed, 
suggesting that most of the toxin was either degraded or had translocated from endosomal 
compartments to the cytosol. In contrast, in ABMA-treated cells, the eGFP-CRM197 signal was much 
stronger, clearly visible as punctuated vesicles in the cells and substantially co-localized with 
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eGFP-CRM197 co-localized partially with mApple-Rab7 in the presence of ABMA, which was not 
the case in DMSO-treated control cells (Fig 4B). These data strongly suggest that ABMA inhibits 
trafficking of EGF and DT by trapping them in acidic and Rab7 positive-compartments, most likely 
late endosomes.
To further characterize the action of ABMA on endo-lysosomal degradation, we investigated 
degradation of red fluorescent DQ Red BSA (DQ-BSA) in live cells at different time points. DQ-
BSA is a fluorogenic substrate for proteases, with a strong fluorescence quenching effect because it is 
heavily labeled with BODIPY dyes. Upon protease-mediated lysosomal hydrolysis of DQ-BSA, the 
dequenched fluorophores produce a bright fluorescence. Cells were pulsed with DQ-BSA for 30 min 
without compounds to allow cellular uptake of the labelled protein and then chased in the presence of 
compounds. After 2 h, fluorescence was visible in DMSO-treated cells, indicating that endocytosed 
DQ-BSA was hydrolyzed in lysosomes (Fig 5A and B). The signal was increased at 6 h but decreased 
at 18 h due to clearance of DQ-BSA fragments and fluorophore. In contrast to the DMSO control 
cells, ABMA-treated cells were barely fluorescent at 2 h. The signal slightly increased at 6 h, but was 
very intense at 18 h. Finally, cells treated with chloroquine, which also acts on late 
endosomes/lysosomes, persistently showed faint fluorescence at all time points (Fig 5A). These data 
suggest that chloroquine completely blocked degradation of DQ-BSA, whereas ABMA delayed 
degradation of DQ-BSA. 
Lysosomal degradation is accomplished by multiple proteases. We examined the activity of cathepsin 
B, one of the major lysosomal proteases, in the lysate of ABMA-treated cells as well as by mixing cell 
lysates with ABMA. Cathepsin B fluorescent substrate was used to monitor the protease’s activity. 
Neither ABMA treated-cells nor cell lysates freshly mixed with ABMA inhibited cleavage of 
cathepsin B substrate (Fig 5C), suggesting that ABMA does not influence lysosomal proteases 
directly or indirectly, in a cell-dependent way. In contrast, chloroquine-treated cells exhibited an 
apparent decreased fluorescence, indicating that chloroquine diminishes cathepsin B activity in a cell-
dependent way. Consistently, the immunofluorescence intensities of cathepsin D were not influenced 
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Altogether, these data demonstrate that the mechanism of action of ABMA is distinct from that of the 
known lysosome inhibitor chloroquine (Fig 5). ABMA delays endo-lysosomal trafficking of 
endocytosed cargoes by trapping them in acidic and Rab7-positive compartments rather than 
inhibiting their lysosomal degradation. 
2.3. ABMA upregulates LC3II and p62, enhances colocalization of p62 with late endosome 
markers Rab7 and Rab9
Macroautophagy, herein referred to as autophagy, is an alternative degradative process in which 
cytosolic proteins or intracellular organelles are sequestered within double-membrane structures 
called autophagosomes for digestion. Precisely, autophagosomes either first fuse with late endosomes 
to form amphisomes, which subsequently fuse with lysosomes, or they fuse directly with lysosomes to 
generate autolysosomes [32], but the latter is primarily based on the yeast system [33]. It is clear now 
that in mammalian cells, several stages of endocytic pathway contribute to efficient autophagy [33]. 
Since ABMA acts on late endosomes, we questioned whether ABMA can thus regulate autophagy. 
The LC3 protein (microtubule-associated protein 1 light chain 3) is used to monitor autophagy. 
Lipidation of LC3 I to LC3 II is an obligatory process for autophagosome expansion and formation. 
We first evaluated whether ABMA changes cellular LC3 I and LC3 II levels by immunoblot. 
Apparently, ABMA (30M) strongly increased endogenous LC3 II in A549 cells (Fig 6A), HeLa 
cells (data not shown) as well as murine RAW 264.7 cells (Fig 6C). The action of ABMA on LC3 II 
increment initiated as early as 0.5 h and continued up to 4 - 6 h (Fig 6C). Notably, the upregulation of 
LC3 II could be induced by the activation of autophagy, or alternatively, by inhibition of autophagic 
degradation [34].Thus, SQSTM1/p62 (hereinafter p62), an autophagy substrate, was monitored in 
parallel with LC3. Activation of autophagy will accelerate p62 degradation, we also observed that 
SMER-28, a small molecule of autophagy activator[35], induced p62 degradation; while bafilomycin 
A1 (Baf A1), autophagic flux blocker, oppositely increased p62 protein level (Fig 6B). Importantly, 
ABMA increased the level of p62 in a time-dependent manner, suggesting a possible inhibition of the 
autophagic degradation (Fig 6C). To further explore the effect of ABMA on autophagic flux, we 
added Baf A1 (100 or 200 nM) in the last 4 hours of ABMA incubation (Fig 6D). ABMA and Baf A1 
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M; 5.43  0.60 and 5.88  0.39-fold for 100 nM and 200 nM of Baf A1). Importantly, addition of 
Baf A1 in the cells treated with ABMA only induced a limited increase of LC3 II (with Baf A1 (100 
nM): 13.49  1.82-fold; with Baf A1 (200 nM): 11.28  0.94-fold). This further indicates that ABMA 
inhibits autophagic flux in a downstream step like Baf A1. 
Next, we used HeLa cells stably expressing GFP-LC3B [36] to investigate the effect of ABMA on the 
autophagic process. LC3B is one of isoforms of LC3, which is equally distributed throughout the 
cytoplasm and also localized in the nucleolar region [37]. ABMA increased GFP-LC3B puncta in a 
dose-dependent way (data not shown). In addition, we compared the effect of chloroquine as well as a 
combination of chloroquine and ABMA on GFP-LC3B level. Chloroquine has long been used to 
inhibit autophagic flux in the late stage. The combined addition of ABMA and chloroquine did not 
further increase the number or size of GFP-LC3B puncta (Fig 6E, n.s p>0.05), suggesting that 
similarly to chloroquine, ABMA acts in the late stage to regulate autophagy by inhibiting the 
autophagic degradation.
p62, as an autophagic substrate, incorporates into completed autophagosomes and is then degraded in 
autolysosomes [38]. ABMA induced an upregulation of p62 by immunoblotting (Fig 6A and 6C). 
Finding out in which specific compartment the undegraded p62 is accumulated can help us to better 
understand the action of ABMA on autophagy. Accordingly, we examined co-localization of 
increased p62 with endosome/lysosome marker proteins Rab7, Rab9 and Lamp1. As we found before, 
Rab7 protein fluorescence was largely increased by ABMA, rather than EEA1 and Lamp1 [12]. 
Importantly, the two upregulated proteins, Rab7 and p62, were strongly co-localized (Fig 7A and 7D), 
increased co-localization of LC3 and Rab7 were also observed (see description below). 
Immunostaining of another late endosomal protein, Rab9, also significantly enhanced its 
immunofluorescence in the presence of ABMA and colocalized with p62 (Fig 7B and 7D). In 
contrast, the lysosome marker Lamp1 was not influenced by ABMA and did not enhance its co-
localization with p62 (Fig 7C and 7D). Considering enhanced co-localization of p62 with the late 
endosome markers Rab7 and Rab9, we hypothesized that ABMA increases the level of the p62 
protein by inhibiting its autophagic degradation. This defective autophagic degradation could be due 
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endosomes. Then, it is only when amphisomes subsequently fuse with lysosomes to generate 
autolysosomes that materials wrapped inside can be degraded properly by lysosomal hydrolases.
2.4. ABMA stimulates the fusion of late endosomes with autophagosomes and disrupts the 
autophagic flux
To further support our hypothesis that ABMA interferes with autophagic degradation by influencing 
amphisomes rather than autolysosomes, ultrastructure morphology of ABMA-treated HeLa cells 
stably expressing GFP-LC3B (Fig 8A) was investigated by transmission electron microscopy (TEM). 
In addition, immunogold labeled antibodies against GFP were employed to investigate localization of 
GFP-LC3B. As shown in Fig 8B, cells stably expressing GFP-LC3B exhibited numerous double-
membrane autophagic compartments in the presence of ABMA, which were absent in DMSO-treated 
cells. These autophagic compartments were further identified by the presence of GFP-LC3B 
recognized by immunogolds (Fig 8B, right panel). Notably, immunogolds specific for GFP-LC3B 
were present in autophagic compartment as well as nascent autophagophore (Fig 8B, right panel, 
white arrow). Moreover, as we found before in A549 cells [12], ABMA induced accumulation of 
MVBs/late endosomes (Fig 8B, arrowhead), which are characterized by round or near-round shape 
with variable intraluminal vesicles (ILVs). Particularly, MVBs/late endosomes were localized mostly 
in the proximity of autophagic compartments suggesting that because of ABMA, late endosomes are 
recruited for autophagy and destined to fuse with autophagic compartments. This further suggests that 
ABMA leads to the accumulation of late endosomes, enhances consequently the formation of 
amphisomes by their fusion with autophagosomes but disrupts the autophagic flux.
3. Discussion
Small-molecule inhibitors of intracellular trafficking have emerged in cell biology studies to explore 
cellular physiology as well as pathogenesis of various disease-inducing agents, especially pathogen-
host interactions [16, 18, 20, 21, 39, 40]. Compared to dominant-negative or genetic modulation of 
specific proteins involved in trafficking, chemical reagents harbor particular advantages to regulate 
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The specific target of ABMA is currently unknown, but the data presented here suggest that its broad-
spectrum anti-toxin and anti-pathogen activity is related to the restriction of endo-lysosomal 
trafficking at the site of late endosomes (Fig 9). Its mechanism of action is distinct from that of 
several other known inhibitors. Because of their distinct mechanisms, the combination of these known 
inhibitors (EGA (Fig 1B), dynasore and tetrandrine (Fig 1D and 1E) as well as Baf A1 [12]) with 
ABMA produced markedly increased efficacy in inhibiting DT cytotoxicity. Our results suggest that 
ABMA may be used as a selective tool for the studies of late endosome-related pathways and function. 
We anticipate that specific modulation of late endosomes by ABMA, combined with other inhibitors 
acting on alternative sites of intracellular trafficking may help to better elucidate entry mechanisms of 
pathogens. 
Late endosomes are considered as essential sorting stations for protein and lipid transport, as well as 
for entry and development of pathogens [14, 41, 42]. Besides their role in the endocytic pathway, late 
endosomes have been shown to have important roles in autophagic processes [15]. Especially, Rab7 
activation plays a unique role in the maturation of autophagosomes [43] and the fusion of 
autophagosomes and amphisomes with lysosomes [15]. 
In this study, we made further observations as the consequences of cell treatment by ABMA: 1) p62 
avoids autophagic degradation but substantially co-localizes with late endosome protein markers 
Rab7 and Rab9, rather than Lamp1 (lysosome marker); 2) cells accumulate autophagic compartments 
shown by TEM, which are characterized by double-membrane, abundance of intraluminal GFP-LC3B 
and undegraded intracellular components but lack of electron-dense degraded materials and single 
membrane (characteristic of autolysosome); 3) autophagic compartments apparently surrounded by 
MVBs/late endosomes accumulate in cells. As a result, we suggest that ABMA stimulates 
amphisomes formation, where p62 (Fig 7) and LC3 (Fig 8) are accumulated and stalled for autophagic 
degradation (Fig 9). 
Deficiency in the autophagic flux can be induced by multiple inhibitors [44], e.g. 3-MA (PI3K 
inhibitor, inhibiting autophagosome formation), bafilomycin and chloroquine (endosome acidification 
inhibitor, impairing fusion of autophagosomes with lysosomes and autolysosome degradation) [45], 
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knowledge, ABMA is the first identified molecule to disrupt the autophagic flux by regulating late 
endosomes and subsequent amphisomes although its precise mechanism is not resolved. This specific 
tool may help to better understand the function and the structure of the amphisome as well as of the 
entire autophagy process.
Being a broad-spectrum anti-pathogen inhibitor, ABMA exhibits variable efficacy according to the 
tested pathogen. Generally, it inhibits viruses (Ebola, Dengue-4 and HSV-2) and parasite (intra-
macrophagic Leishmania infantum amastigotes) more powerfully (IC50s < 10 µM) than toxins (IC50s > 
60 µM for DT, TcdB and lethal toxin)[12, 23]. This implies that ABMA’s action on late endosomes 
may generate multifaceted consequences, which are more productive and selective to restrict infection 
and/or development of certain viruses and parasites. Mounting studies have demonstrated that 
autophagy can be hijacked by viruses and parasites for their infection of cells and survival [47, 48], 
and thus, regulation of autophagy may serve as an alternative strategy for anti-infectious treatment 
[49]. Further research is needed to clarify the relevance of autophagy regulation by ABMA to its 
inhibitory mechanism on viral and parasitic infection.
In conclusion, ABMA is not only a host-targeted inhibitor for toxins, bacteria, viruses and parasites 
but also a potent tool for dissecting infection mechanism of known or emerging pathogens at the level 
of endocytic and autophagic processes. 
4. Materials and Methods 
4.1. Materials and reagents
1-adamantyl (5-bromo-2-methoxybenzyl) amine (ABMA) was purchased from Chembridge (ID: 
5570320, San Diego, CA, USA). The following products were purchased from the indicated 
commercial sources: L-[14C(U)]-leucine was from Perkin-Elmer; DMSO (D4540), DT (D0564), 
bafilomycin A1 (B1793), Hoechst 33342 (14533), filipin III (F4767), Gelatin (G7765), EGA 
(SML1006), G418 (G8168), SMER28 (S8197), anti-LC3B (L7543, 1:2000 WB), anti-p62 (P0067, 
1:1000 WB), anti-Lamp1 (L1418, 1:100 IF) were purchased from Sigma; anti-Rab9 (#5118, 1:200 IF) 
was from cell signaling; Anti-Rab7 (ab137029, 1:200 IF), anti-actin (ab3280, 1:2000 WB) and 
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1:10000 IF), DQTM Red BSA (D-112051, 10g/ml IF), Alexa555-EGF (E-35350, 10 μg/mL IF), Anti-
Cathepsin D (PA5-17353, 1:200 IF) were from ThermoFisher Scientific; anti-p62 (H00008878-M01, 
1:200 IF) was from Abnova; anti-GFP antibody (ab6556, 1:20 TEM) was from Abcam and Goat-anti-
rabbit IgG (H+L) antibody coupled with 10 nm gold particles (810.011, 1:20 TEM) was from Aurion. 
A549 and HeLa cells (ATCC) were cultured in DMEM with 10% fetal bovine serum (FCS). HeLa 
cells stably expressing GFP-LC3B were grown in RPMI with 10% FCS and 500 μg/mL G418 [50]. 
HeLa cells stably expressing mApple-Rab7 were grown in high-glucose DMEM with 10% FCS and 
1% sodium pyruvate. All cells were authenticated, checked for contamination and cultured at 37°C 
with 5% CO2.
4.2 Toxin intoxication assays
For detailed experimental procedures, see previous description [12]. Briefly, A549 cells in the 
presence of various concentrations of compounds solubilized in DMSO (final DMSO concentration 
was 0.1% in controls and in treated cells) were incubated with increasing doses of DT in 96-well 
Cytostar-TTM scintillating bottom plates (Perkin Elmer). After 20 h, the medium was replaced with 
DMEM without leucine (Eurobio) containing 10% fetal bovine serum, 2 mM L-glutamine, 0.1 mM 
non-essential amino acids, supplemented with 0.5 μCi/mL [14C]-leucine. The cells were grown for an 
additional 4 h at 37 °C and then protein biosynthesis was determined by measuring the incorporation 
of radiolabeled-leucine into cells using a Wallac 1450 MicroBeta scintillation counter (Perkin-Elmer).
Drug concentration was plotted against the corresponding percentage of protection of cells, and the 
50% efficacy concentration (EC50) was calculated by nonlinear regression using the Prism software 
package (Graphpad Inc., San Diego, CA).
4.3 Molecular cloning, expression and affinity purification of recombinant His-eGFP-CRM197 
(eGFP-CRM197)
Basis for molecular cloning was the plasmid pTRC99A-myc-DTE148S, which was kindly gifted by 
Dr. Emmanuel Lemichez (Paris, France). pTRC99A-His-DTG52E also known as pTRC99A-His-
CRM197 was created using site directed mutagenesis and overhang PCR with traditional cloning 
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(Freiburg, Germany) and inserted into pTRC99A-His-CRM197 using In-Fusion® (Clontech) cloning 
resulting in pTRC99A-His-eGFP-CRM197, which includes a GSG-linker between eGFP and 
CRM197.
The expression plasmid pTRC99A-His-eGFP-CRM197 was transformed into competent Shuffle® T7 
Express (NEB). A single clone was picked for over day culture in 5 mL LB-Amp (LB medium 
[tryptone 10 g/L, yeast extract 5 g/L, NaCl 10 g/L] containing Ampicillin [100 mg/L]) at 30 °C and 
180 rpm. The culture was then transferred into an Erlenmeyer flask with 120 mL fresh LB-Amp for 
overnight culture at 30 °C and 180 rpm. The following day, two Erlenmeyer flasks with 1 L of LB-
Amp each were inoculated with 50 mL of overnight culture per flask and further incubated at 30 °C 
and 180 rpm. Upon reaching OD600 of 0.4 the expression was induced using 1 mM IPTG and 
temperature was shifted to 16 °C for overnight incubation at 180 rpm. Cultures were centrifuged at 
5500 g for 7 min. Pellets were resuspended in equilibration buffer (Tris-HCl 50 mM, NaCl 300 mM, 
imidazole 20 mM, pH 7.5) and frozen. Subsequently, pellets were thawed, supplied with 1 mM 
PMSF, stored on ice and sonicated (10 pulses with 30 s and amplitude of ~ 40 % with intermediate 
pauses of 30 s on ice). The solution was then centrifuged at 13000 g for 30 min at 4 °C and filtered 
through 0.45 µm and 0.2 µm syringe filters. Purification was performed using an ÄKTA® FPLC 
system with a 1 mL Ni-NTA column. Protein was then eluted with elution buffer (Tris-HCl 50 mM, 
NaCl 300 mM, imidazole 500 mM, pH 7.5), protein containing fractions were pooled and buffer was 
exchanged to PBS using Vivaspin 20® centrifugal concentrators with 30 kDa MWCO (3 times 
refilled with PBS). Protein was further stored at -80 °C.
4.4 Generation of HeLa cells stably expressing mApple-Rab7
HeLa CCL2 cells (ATCC) were maintained in DMEM supplemented with 10% fetal calf serum 
(BioConcept, Switzerland), 2 mM L-glutamine, 1 mM sodium pyruvate, and penicillin and 
streptomycin antibiotics). mApple-Rab7a was a gift from Michael Davidson (Addgene plasmid 
#54945; http://n2t.net/addgene:54945; RRID: Addgene_54945). The mApple-Rab7 plasmid was 
linearized using the AseI restriction enzyme (NEB), and transfected into HeLa cells using TurboFect 
transfection reagent (Thermo Fisher). Medium was supplemented with 500 μg/mL G418 (G8168, 
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sorted by FACS ARIA III (Biozentrum FACS Core Facility) and re-sorted 15 days later into 96-well 
plates for single cell clonal expansion. A healthy clone displaying characteristic Rab7 distribution was 
selected for further experiments.
4.5 Immunocytochemistry 
Cells were grown on glass coverslips one day before experiments. Following treatments, cells were 
rinsed with PBS, fixed with 4% paraformaldehyde-PBS for 20 min at room temperature or with 
methanol at -20°C for 10 min. After three washes with PBS, cells were permeabilized with 0.1% 
saponin for 5 min. Subsequently, cells were blocked in 0.5% gelatin-PBS and then stained with 
antibodies. Finally, the coverslips were mounted on glass slides and imaged using an inverted 
microscope (Ti-U, Nikon) or confocal microscope (SP8X, Leica) with a 63X PLAN APO oil-
immersion objective. The co-localization analysis was quantified according to Pearson’s correlation 
coefficient of two interested proteins by Image J software with JACop plug-in [51].
4.6 EGF and eGFP-CRM197 trafficking
Cells were incubated with Alexa555-EGF (10 μg/mL) for 30 min and then washed three times with 
PBS before being treated with compounds for the indicated time. eGFP-CRM197 (1:150) (37°C, 5% 
CO2) was added with compounds into cells for indicated time. Images of live cells were obtained as 
same as 4.3.
4.7 DQ-BSA degradation
A549 cells were incubated with DQ-BSA (DQTM Red BSA) at a concentration of 10 μg/mL for 30 
min (37°C, 5% CO2). The cells were then washed three times with PBS before being treated with 
compounds for the indicated time. Photographs of live cells were obtained using an inverted 
microscope (Ti-U, Nikon).
4.8 TEM 
HeLa cells stably expressing GFP-LC3B were incubated with ABMA or DMSO for 24 h. Next, cells 
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M phosphate buffer (pH 7.4), then they were washed with 0.1 M phosphate buffer (pH 7.4) and 
detached from the flask by gently scrapping. Cells were centrifuged (1200 g, 2 min) in 2% low 
melting point agarose to obtain concentrated pellets in 1 mm3. Dehydration was performed at 4°C 
with 10%, 30% and 50% ethanol baths, and then at -20°C with 70%, 90% and 100% ethanol baths. 
Samples were finally kept in absolute ethanol before the embedding process. Embedding in graded 
series (25-50-75-100-100-100%) of resin (LR White Resin, Agar Scientific, Oxford instruments) 
mixed with ethanol was processed on 3 days at -20°C. Subsequently, blocs were polymerized for 24 h 
at -20°C and for 24 h at RT under UV light. Ultrathin sections (80 nm) were cut by an ultramicrotome 
EM UC6 (Leica Microsystems) and collected on Formvar carbon-coated nickel grids. 
Immunogold labelling was performed as follows. Ultrathin sections were pretreated with PBS-
Tween20 0.5% for 5 min, PBS-Glycine 50 mM for 5 min twice, and then blocked in a blocking 
solution for goat-gold conjugates (Aurion) for 30 min followed by washing with PBS-BSA-c 
(Aurion, 900.099). The anti-GFP primary antibody diluted in PBS-BSA-c (1:20) was employed on 
sections for 1 h. Sections were washed with PBS four times, with PBS-BSA-c twice, then incubated 
with the Goat-anti-rabbit IgG (H+L) secondary antibody coupled with 10 nm gold particles for 30 
min. Finally, sections were washed with PBS four times and ten times with water before staining in 
uranyl acetate (8 min) and lead citrate (2 min). 
Observations were made with a JEOL JEM-1400 transmission electron microscope operating at 80 
kV. Images were acquired using a postcolumn high-resolution (11 megapixels) high-speed camera 
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Table 1. Known anti-toxin and anti-pathogen spectra of ABMA and EGA [8, 12, 21, 23, 26, 27]







Lethal toxin from Bacillus anthracis (LT)
Diphtheria toxin (DT)
Exotoxin A (PE) from P. aeruginosa
Botulinum neurotoxin A, B, C2 and D 
(BoNT/A, B, C2 and D) from Clostridium 
botulinum neurotoxins
Iota toxin from Clostridium perfringens
C2 toxin from Clostridium botulinum
Cytolethal distending toxins from 




Lethal toxin from Bacillus anthracis 
(LT)
Toxin B from Clostridium difficile 
(TcdB)










Cytolethal distending toxins from Escherichia. 
coli (Ec-CDT)
Toxins A and B from Clostridium difficile
Shiga-like toxin 2 (Stx2) from 
Escherichia. coli
Botulinum neurotoxin A (BoNT/A) 






Vesicular stomatitis virus (VSV)



















































This article is protected by copyright. All rights reserved
Figure 1. Combination of ABMA and EGA substantially improves inhibitory effect on 
cytotoxicity of DT in A549 cells. (A) EGA inhibits cytotoxicity of diphtheria toxin (DT) by 
measuring the incorporation of 14C labeled-leucine into newly synthesized proteins in A549 
cells with an EC50 of 9.67 M. Results are from one representative experiment (n=2). (B) 
ABMA (30 M), EGA (1.25 M) and combination of both reversed DT-induced protein 
biosynthesis inhibition. Each point corresponds to mean ± S.E.M. from a representative 
experiment (n=3). (C) Protection factors (R) of ABMA (30 M), EGA (1.25 M (B) or 2.5 
M) and of their combination on cytotoxicity of DT. Results are shown as mean  S.E.M. 
from 3 independent experiments. (D) Dynasore (80 M) and (E) tetrandrine (Tet, 7.5 M) 
both have apparent synergistic effects with ABMA (30 M) in inhibiting cytotoxicity of DT. 
Right: R values of each drug and their combination are from one representative experiment 
(n=2). Experimental procedure is as same as Fig 1B, except that dynasore was employed in 
serum-free medium to sustain its activity, and intoxication time was 6 h.
Figure 2. ABMA induces accumulation of EGF in acidic compartments. (A) A549 cells 
were pulsed with Alexa555-EGF for 30 min at 37°C and then chased for 4 h at 37°C in 
presence of DMSO, ABMA (60 µM), EGA (30 µM) or Tet (7.5 µM) respectively. Live-cell 
images were obtained with an inverted microscope (Ti-U, Nikon). Representative images are 
from one of three experiments. Right, Fluorescence intensity of at least 30 cells from each 
condition was quantified and analyzed by Image J. Results are shown as mean  S.E.M., A.U 
means arbitrary unit. Statistical significance was tested using unpaired t-test with Welch’s 
correction, compared to DMSO control (n.s, p > 0.05; * p < 0.05; *** p < 0.001).  (B) A549 
cells were pulsed for 30 min at 37°C with Alexa555-EGF and chased in the presence of 
DMSO or ABMA for 4 h. Hoechst 33342 (blue) and Lysotracker Green (B) were added 
during the last 30 min of incubation.  Right, Pearson’s coefficients of two fluorescence were 
analyzed by Image J software with JACop plug-in. Values are shown as mean ± S.E.M. from 
25-30 cells of two independent experiments. Statistical significance was tested using 
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Figure 3. Identification of His-eGFP-CRM197 (eGFP-CRM197). (A) Purified protein 
was identified by SDS-PAGE and Coomassie blue staining. BSA at indicated concentrations 
was used as quantification control. (B) Intracellular fluorescence of eGFP-CRM197. A549 
cells were pulsed with eGFP-CRM197 (1:150) for 45 min and directly observed by an 
inverted microscope (Ti-U, Nikon). Images shown are representative of two independent 
experiments. Scale bar, 10 μm.
Figure 4. ABMA induces accumulation of catalytically inactive DT mutant (eGFP-
CRM197) in acidic compartments. A549 cells (A) or HeLa cells stably expressing 
mApple-Rab7 (B) were pulsed with eGFP-CRM197 (1: 150) for 5 h in complete medium in 
the presence of DMSO or 60 μM ABMA. Hoechst 33342 (blue) and Lysotracker DeepRed 
(A) was added during the last 30 min. Images of live cells were obtained by confocal 
microscopy (SP8X, Leica). Right, Pearson’s correlation coefficients were analyzed as same 
as Fig 2B. Statistical significance was tested using unpaired t-tests with Welch’s correction 
(*** p < 0.001). Scale bar, 10 μm.
Figure 5. ABMA delays but does not block degradation of DQ-BSA. (A) A549 cells were 
pulsed with DQ-BSA for 30 min at 37°C, then chased in the presence of DMSO, ABMA 
(60M) or CQ (60M) for the indicated time (n=3). Live cells were imaged by an inverted 
microscope (Ti-U, Nikon). Scale bar, 10 μm. (B) Fluorescence intensity of at least 30 cells 
was quantified and analyzed by Image J. Results are shown as mean  S.E.M. from one 
representative experiment (n=3). A.U means arbitrary unit. Statistical significance was tested 
using unpaired t-tests with Welch’s correction, compared to DMSO control (** p < 0.01; *** 
p < 0.001). (C) Cathepsin B activity assay. Cell-free assay: A549 cell lysate mixed with 
cathepsin B substrate labeled with fluorescent probe, was incubated with DMSO, ABMA (60 
M) or cathepsin B inhibitor (positive control, provided with the kit) for 1 h (left). Cell-
dependent assay: lysates from A549 cells treated 24 h with compounds (ABMA or CQ, both 
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= 400/505 nm) from cleaved fluorescent substrate was determined by imaging reader 
(Cytation 5, Biotek). Cathepsin B substrate replaced by buffer was used as blank control. 
Data represent the mean ± S.D. from duplicate well of one representative experiment (n=2), 
normalized to DMSO treatment. (D) Immunofluorescence of cathepsin D from A549 cells 
incubated with DMSO or ABMA (60 M) for 18 h. Images were obtained by confocal 
microscopy (SP8X, Leica), and images shown are representative of three experiment. Scale 
bar, 10 m.
Figure 6. ABMA upregulates LC3 II and p62 level. (A) Immunoblot of LC3 and p62 from 
lysates of A549 cells treated with ABMA at 30 μM for 16 h.  (B) Immunoblot of p62 from 
A549 cell lysates which are respectively treated by DMSO, Baf A1 (100 nM) or SMER 28 
(45 M) for 5 h. Loading amount is examined by total proteins of each lysates imaged and 
analyzed by Gel Doc™ EX system (BIO-RAD). p62 amounts normalized to total loading 
proteins is shown as mean  S.E.M. from 2 independent experiments.  (C) Immunoblot of 
LC3 and p62 from lysates of RAW264.7 treated with ABMA at 30 µM for the indicated 
time. LC3 II and p62  (A and C) were quantified and normalized to actin, shown as mean  
S.E.M. (n=3). Statistical significance compared to 0 h was tested using paired t-tests (n.s, p > 
0.5; *p < 0.05; ** p < 0.01; *** p < 0.001). (D) Autophagic flux with Baf A1 was analyzed 
by LC3 protein monitoring. ABMA (60 M, 20h) incubated-A549 cells were treated with 
100 nM or 200 nM Baf A1/without (-) Baf A1 during last 4h. Quantification of relative LC3 
II/Actin was shown as mean  S.E.M. (n=2). (E) HeLa cells stably expressing GFP-LC3B 
were incubated with chloroquine (CQ, 60 M), or both CQ and ABMA (60 M) for 16 h. 
Green fluorescence puncta and their sizes of at least 30 cells were analyzed by Image J. 
Statistical significance was tested using unpaired t-tests with Welch’s correction (n.s, p > 0.5; 
*p < 0.05; ** p < 0.01; *** p < 0.001). Scale bar, 10 μm.
Figure 7. ABMA impairs degradation of p62 and enhances its localization in Rab7 and 
Rab9-positive vesicles. Immunostaining for Rab7 (A), Rab9 (B) or Lamp1 (C) and p62 in 
A549 cells pre-treated in DMSO or ABMA (60 M) for 18 hr. Nuclei were stained with 
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Image J software with JACop plug-in. Values from at least 30 cells of 3 independent 
experiments are shown as mean ± S.E.M, statistical significance was tested using unpaired t-
tests with Welch’s correction, compared to DMSO control (n.s, p > 0.5; *** p < 0.001).
Figure 8. ABMA impairs autophagic flux by accumulation of amphisomes. HeLa cells 
stably expressing GFP-LC3B were incubated for 24 h with ABMA (30 µM) or DMSO as 
control. (A) Immunofluorescence of Rab7 and GFP-LC3B. Images shown are representative 
of two experiment obtained by confocal microscopy (SP8X, Leica).  Scale bar, 10 m. (B) 
Cells were processed for electron microscopy and stained by anti-GFP antibodies followed 
by immuno-gold labelling. Representative electron micrographs of sections are shown. 
Arrowheads indicate MVBs/late endosomes and arrows indicate immuno-gold labelled GFP-
LC3B.
Figure 9. Model depicting the role of ABMA in the regulation of endo-lysosomal 
pathway and autophagic flux as well as its role as a pharmacological inhibitor of toxin 
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